HLG-HM41CTB-100μg / 询价
HLG-HM41CTB-500μg / 询价
HLG-HM41CTB-500μgx2 / 询价
Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein
Recombinant Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus,tetramer is assembled by biotinylated monomer and streptavidin.It contains Gly25-Thr305(HLA-G), Ile21-Met119(B2M) and RIIPRHLQL peptide [Accession | P17693-1(HLA-G)&P61769(B2M)&RIIPRHLQL].
The protein has a predicted MW of 258 kDa. Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.
> 95% as determined by Bis-Tris PAGE
Less than 1EU per μg by the LAL method.
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.
Immobilized Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His Tag at 1μg/ml (100μl/well) on the streptavidin precoated plate (5μg/ml). Dose response curve for Anti-HLA-G Antibody, hFc Tag with the EC50 of 7.2ng/ml determined by ELISA (QC Test).
Serial dilutions of Anti-LILRB2 Antibody were added into Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His Tag: Human LILRB2, mFc Tag binding reactioins. The half maximal inhibitiory concentration (IC50) is 0.29μg/ml.
Human LILRB2, hFc Tag captured on CM5 Chip via Protein A can bind Biotinylated Human HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His-Avi Tag with an affinity constant of 4.38 nM as determined in SPR assay (Biacore T200).
HLA-G is a molecule that was first known to confer protection to the fetus from destruction by the immune system of its mother, thus critically contributing to fetal-maternal tolerance. The first functional finding constituted the basis for HLA-G research and can be summarized as such: HLA-G, membrane-bound or soluble, strongly binds its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic cells), inhibits the functions of these effectors, and so induces immune inhibition.
HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G
(1) Krijgsman D, Roelands J, Hendrickx W, Bedognetti D, Kuppen PJK. HLA-G: A New Immune Checkpoint in Cancer? Int J Mol Sci. 2020 Jun 25;21(12):4528. doi: 10.3390/ijms21124528. PMID: 32630545; PMCID: PMC7350262.
